5AM Venture Management LLC bought a new stake in Pharvaris N.V. (NASDAQ:PHVS - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 797,600 shares of the company's stock, valued at approximately $27,581,008. Pharvaris comprises 0.0% of 5AM Venture Management LLC's investment portfolio, making the stock its 4th biggest position. 5AM Venture Management LLC owned 1.22% of Pharvaris at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently modified their holdings of PHVS. Quantbot Technologies LP purchased a new position in shares of Pharvaris in the 2nd quarter valued at approximately $41,000. JPMorgan Chase & Co. grew its stake in shares of Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company's stock valued at $59,000 after purchasing an additional 783 shares during the last quarter. Barclays PLC purchased a new position in Pharvaris during the fourth quarter worth about $77,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in Pharvaris during the fourth quarter worth about $86,000. Finally, CoreCap Advisors LLC purchased a new position in Pharvaris during the second quarter worth about $93,000.
Analyst Ratings Changes
PHVS has been the subject of several analyst reports. Citizens Jmp increased their price target on shares of Pharvaris from $74.00 to $75.00 and gave the stock a "market outperform" rating in a report on Thursday, August 13th. Weiss Ratings reissued a "sell (d-)" rating on shares of Pharvaris in a report on Friday, July 17th. HSBC raised Pharvaris to an "overweight" rating in a report on Thursday, August 13th. New Street Research set a $60.00 price target on Pharvaris in a report on Friday, August 14th. Finally, Wall Street Zen cut Pharvaris from a "hold" rating to a "sell" rating in a report on Saturday, July 18th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Pharvaris has a consensus rating of "Moderate Buy" and an average target price of $51.08.
Read Our Latest Stock Analysis on PHVS
Insider Transactions at Pharvaris
In related news, Director Johannes Gerardus Chri Schikan sold 30,712 shares of Pharvaris stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total transaction of $1,089,968.88. Following the completion of the transaction, the director directly owned 315,167 shares of the company's stock, valued at approximately $11,185,276.83. The trade was a 8.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Anna Nijdam sold 2,670 shares of Pharvaris stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $30.87, for a total value of $82,422.90. Following the transaction, the insider directly owned 46,275 shares of the company's stock, valued at approximately $1,428,509.25. This represents a 5.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 121,325 shares of company stock valued at $4,270,425. Company insiders own 11.84% of the company's stock.
Pharvaris Price Performance
PHVS opened at $35.32 on Friday. The business has a 50 day simple moving average of $34.61 and a 200-day simple moving average of $30.75. The stock has a market capitalization of $2.31 billion, a P/E ratio of -11.58 and a beta of -2.31. Pharvaris N.V. has a 12 month low of $20.65 and a 12 month high of $38.13.
Pharvaris (NASDAQ:PHVS - Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Research analysts anticipate that Pharvaris N.V. will post -3.15 EPS for the current year.
Pharvaris Profile
(
Free Report)
Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.
The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.
Further Reading
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
